LH

Business Context and Reporting Period

Company: Laboratory Corporation of America Holdings (LabCorp)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2006
Business Overview: LabCorp operates as a leading provider of clinical laboratory testing services. The company reported strong growth in genomic and esoteric testing volumes, driven in part by the 2005 acquisition of Esoterix, Inc. The company is a large accelerated filer with 125.2 million shares of common stock outstanding as of July 26, 2006.

Key Financial Metrics

Note: Total Debt includes $549.9 million in zero-coupon convertible subordinated notes and $603.3 million in long-term senior notes. Cash and short-term investments include $185.7 million in auction rate securities.

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 5.9% year-over-year for the quarter and 7.9% for the six-month period. Growth was driven by a 1.8% increase in accession volume (quarterly) and a 4.1% price increase.
• Profitability: Net earnings rose 9.8% for the quarter and 7.7% for the six-month period compared to 2005. Operating margins improved slightly as cost of sales as a percentage of net sales decreased from 57.2% to 56.5% (quarterly).
• Expense Increases: Selling, general, and administrative (SG&A) expenses increased due to the adoption of SFAS 123(R) (stock-based compensation) and investments in the sales force. Interest expense rose significantly due to the issuance of 5.625% Senior Notes in December 2005.
• Balance Sheet: Short-term investments increased significantly to $185.7 million (from $17.7 million at year-end 2005) due to the reclassification of auction rate securities. Cash and cash equivalents decreased to $16.6 million.

Guidance, Outlook, and Risks

• Capital Expenditures: Management expects total capital expenditures for 2006 to range between $95.0 million and $110.0 million, focused on customer retention, scientific differentiation, and IT connectivity.
• Share Repurchases: The company repurchased $185.0 million of stock in the first six months of 2006. Approximately $100.2 million in authorization remains available.
• Debt Obligations: Holders of zero-coupon subordinated notes may require the company to purchase notes on September 11, 2006, at a potential cost of $552.0 million. Management believes it has sufficient liquidity to meet this obligation.
• Legal Proceedings: A shareholder class action regarding securities fraud was dismissed in May 2006. A patent infringement case (Metabolite) was dismissed by the Supreme Court and remanded for further proceedings; management does not expect a material adverse effect.
• Risk Factors: Key risks include changes in reimbursement policies (Medicare/Medicaid), regulatory compliance (CLIA, HIPAA), competition, and the ability to maintain days sales outstanding levels.

Investor Verification Checklist

• Debt Refinancing: Verify the company's ability to fund the potential $552 million put option on zero-coupon notes due September 11, 2006, given the current cash balance of $16.6 million.
• Stock-Based Compensation: Review the impact of the new SFAS 123(R) standard on future earnings, which reduced net earnings by $6.7 million in the first half of 2006.
• Liquidity Composition: Confirm the liquidity status of the $185.7 million in auction rate securities (ARS) and variable rate demand notes (VRDN) classified as short-term investments.
• Reimbursement Trends: Monitor the "effective bad debt expense rate" and payer mix shifts, as these are critical drivers of the company's gross margin stability.
• Acquisition Integration: Assess the ongoing integration and performance contribution of the Esoterix, Inc. acquisition to the reported volume growth in genomic testing.